# Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

> **NCT03806127** · PHASE2 · COMPLETED · sponsor: **Urovant Sciences GmbH** · enrollment: 222 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Vibegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03806127
- **Lead sponsor:** Urovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-31
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-10-06
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806127, "Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03806127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*